Dermatofibrosarcoma protuberans is a locally aggressive superficial mesenchymal neoplasm. It typically occurs in adulthood, and has been reported to have a slight male predilection. Tumors have a characteristic histopathologic appearance, including: storiform architecture, infiltrative "honeycomb" growth within subcutaneous adipose tissue, and immunoreactivity for CD34. Virtually all molecularly characterized cases to date have been found to harbor a COL1A1-PDGFB fusion product. Following identification of an index patient with a novel COL6A3-PDGFD fusion gene, we undertook a molecular investigation, using a combination of RNA sequencing and fluorescence in situ hybridization (FISH), to assess the prevalence of PDGFD rearrangement in dermatofibrosarcoma protuberans (N = 63). Three additional patients were found to have balanced PDGFD rearrangements. Interestingly, all 4 tumors arose on the breast of females. As a result, we subsequently examined 16 additional cases of primary breast dermatofibrosarcoma protuberans, identifying 2 additional tumors with PDGFD rearrangement. The morphology and immunophenotype of all 6 cases was analogous to those with the canonical COL1A1-PDGFB fusion; none of the cases showed fibrosarcomatous transformation. This study illustrates that the COL6A3-PDGFD fusion product is rare in dermatofibrosarcoma protuberans, and associated with an apparent predilection for breast. An awareness of this variant is important for pathologists, as it will not be detected using conventional reverse transcription polymerase chain reaction or FISH-based diagnostic assays for dermatofibrosarcoma protuberans.
| INTRODUCTION
Dermatofibrosarcoma protuberans is a fibroblastic neoplasm originating in the dermis and/or superficial subcutis. 1 It may arise throughout the body, but most commonly involves the trunk and extremities. 2 Tumors typically occur in early-to-mid adulthood, although it is known to have a wide range of involvement 2, 3 ; it is reported to have a slight male predilection. 2, 3 The clinical behavior is generally characterized by local aggressiveness. 1 Complete surgical resection, with widely negative margins, is generally curative. 2 Morphologically, most tumors are composed of spindle cells in a prominent storiform/whorled pattern. 2, 3 Peripherally, there is often infiltration of subcutaneous adipose tissue yielding a characteristic "honeycomb" pattern. Tumors tend to spare adnexal structures. The cells are monomorphic and generally have only minimal mitotic activity. 2 Multiple morphologic variants exist, including, for example, those associated with melanin pigmentation (Bednar tumor), 4 giant cells, 5, 6 prominent myxoid stroma, 7 and myoid differentiation. 8 A subset of cases may undergo fibrosarcomatous transformation (fibrosarcoma ex-dermatofibrosarcoma protuberans) which is associated with frequent local recurrence (58%), as well as metastasis (15%) 9 ; in addition to areas of conventional dermatofibrosarcoma protuberans, these tumors tend to have a fascicular-herringbone architecture, and increased cellularity and mitotic activity. 9 Additionally, a pleomorphic variant of dermatofibrosarcoma protuberans has recently been reported. 10 Most tumors exhibit diffuse immunoreactivity for CD34, 11 but this may be diminished-to-absent in a proportion of cases with fibrosarcomatous transformation 12 ; myoid differentiation is highlighted by smooth muscle actin. 8 Virtually all molecularly characterized cases to date have been reported to have a COL1A1-PDGFB fusion gene. The concomitant chimeric protein causes autocrine activation of the PDGFRB protein-tyrosine kinase, which leads to disinhibited cell proliferation 13 ; consequently, in advanced cases, this provides a rationale for targeted therapy using tyrosine kinase inhibitors, such as imatinib. 
| Immunohistochemistry
Formalin-fixed paraffin-embedded tissue blocks were cut at 4 μm and stained for CD34, desmin, smooth muscle actin, S100, and keratin (AE1/AE3) using standard techniques (Supporting Information   Table S1 ). Appropriate on-slide positive controls were used throughout. Scoring of tumors was based on the percentage of positive cells (0: no staining; 1+: <5%; 2+: 5%-25%; 3+: 26%-50%; 4+: 51%-75%;
and 5+: 76%-100%). 
| RNA sequencing

| Fluorescence in situ hybridization
Fluorescence in situ hybridization for PDGFB and PDGFD was performed as previously described in detail (Supporting Information   Table S2 ). 17 on the breast. Clinically, none were reported to be protuberant and the average size was 1.5 cm (range, 1.0-2.1 cm). Morphologically, ; this subsequently led to the identification of the t(17;22)(q22; q13) event. [21] [22] [23] Ultimately the COL1A1-PDGFB fusion gene was cloned, which fairly consistently pairs exon 2 of PDGFB with numerous potential exons of COL1A1. 13 This fusion product has been identified in 85%-96% of cases. [24] [25] [26] [27] [28] [29] [30] The incidence appears to increase with the application of more sensitive detection assays; nevertheless, this still implies that a subset of cases may have an alternate fusion gene. This is supported by cytogenetic studies which raise the possibility of other translocation events, including: t(2;17)(q33;q25), 31 t (9;22)(q32;q12.2), 32 t(5;8)(q13-14;p21), 33 and t(X;7)(q21.2;q11.2). 34 None of these fusions encompass PDGFD or COL6A3, suggesting these may represent additional potential fusion partners in dermatofibrosarcoma protuberans. Recently an alternative PDGFB fusion partner was identified-COL1A2-PDGFB in a tumor that was otherwise typical of dermatofibrosarcoma protuberans. 29 In the routine work-up of a case of dermatofibrosarcoma protuberans using RNA-Seq we discovered a novel COL6A3-PDGFD fusion variant. We proceeded to test a cohort of 63 patients, identifying PDGFD rearrangement in four (6.3%) tumors, while 58 (92%) were confirmed to possess the canonical PDGFB rearrangement (Table 1) .
Rather surprisingly, all four patients with the variant fusion were women, and each tumor originated from the breast as a non-protuberant, but palpable, subcutaneous mass. As a result, a second cohort of patients-specifically, those with dermatofibrosarcoma protuberans occurring on the breast/chest-was investigated to determine whether this anatomic site may be enriched for the variant PDGFD fusion. A total of 15 additional cases were examined, with two additional cases found to harbor PDGFD rearrangement (13.3%) ( Table 1); 12 contained conventional PDGFB rearrangement (80%); and, one patient was negative for both PDGFB and PDGFD rearrangement. All 6 patients with the PDGFD variant fusion were female (100%) and all tumors were located on the breast (100%), predominantly the left (83%). Three of these cases were tested by RNA-Seq, which established COL6A3 as the PDGFD fusion partner. Each of these six cases was morphologically typical of dermatofibrosarcoma protuberans, though dermal involvement could only be documented in a single case. All cases had prominent storiform growth, infiltration of subcutaneous adipose tissue with a "honeycomb" pattern, and minimal nuclear atypia and mitotic activity; all of the cases exhibited diffuse CD34 expression (Figure 1 ). In addition to facilitating discovery of the variant COL6A3-PDGFD fusion gene, RNA-Seq in this series identified two cases with PDGFB rearrangement that were found to be negative by conventional FISH testing (Patients A6 and A7). This suggests a possible limitation to FISH testing in a minority of cases.
The COL1A1-PDGFB fusion is sufficiently prevalent in dermatofibrosarcoma protuberans that it has led to the suggestion that, in many cases, the absence of this event implies an alternative diagnosis. 33 Variant fusions are nevertheless recognized, and with the report of a case with a variant COL1A2-PDGFB fusion it was proposed that constitutive expression of PDGFB is the fundamental mechanism of tumorigenesis in dermatofibrosarcoma protuberans. 29 To our knowledge, the COL6A3-PDGFD fusion gene has not previously been characterized, and its relationship to the conventional COL1A1-PDGFB fusion gene is unclear. COL6A3 encodes collagen type VI alpha 3 chain, a microfibrillar component of the extracellular matrix, which is widely present in most connective tissues. 35 Fusions involving COL6A3 are known to occur in other neoplasms, notably tenosynovial giant cell tumor, which frequently contains a COL6A3-CSF1 fusion 36 ; in this context, the role of COL6A3 is believed to be that of a strong promoter. 37 PDGFD is a member of the platelet-derived growth factor family, a family of disulfide-bonded dimeric isoforms, also known as a mesenchymal growth factor 38, 39 ; recently, it has been proposed to have an important role in so-called "epithelial mesenchymal transition." 40 The chimeric proteins arising from COL6A3-PDGFD and COL1A1-PDGFB fusion genes both retain the PDGF domain 13, 41 ; and, similar to PDGFB, 42 PDGFD binds and activates PDGFR-β 38, 43 ; This suggests that, despite a different ligand arising with the variant PDGFD chimera, it may nevertheless result in a similar pattern of autocrine activation via PDGFRB receptor tyrosine kinase signaling as conventional PDGFB. Moreover, by RNA-Seq, tumors with 33 Furthermore, similar to dermatofibrosarcoma protuberans with conventional PDGFB fusions, the variant PDGFD fusion group also showed up-regulation of PDGFRB, which suggests that therapeutic targeting with tyrosine kinase inhibitors, such as imatinib, might be an option in locally advanced or metastatic lesions. [44] [45] [46] 
